mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double‐Blind, Placebo‐Controlled Futility Trial and 1‐Year Biomarker Longitudinal Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Movement Disorders"
DOI: 10.1002/mds.28923
Abstract: Multiple system atrophy (MSA) is a fatal neurodegenerative disease characterized by the aggregation of α‐synuclein in glia and neurons. Sirolimus (rapamycin) is an mTOR inhibitor that promotes α‐synuclein autophagy and reduces its associated neurotoxicity in… read more here.
Keywords: system atrophy; multiple system; mtor inhibition; inhibition sirolimus ... See more keywords